Pharmaceuticals & Healthcare Report Saudi Arabia

June 24, 2007 - PRLog -- Independent 5-year pharmaceutical and healthcare industry forecasts for Saudi Arabia.

Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Saudi Arabian pharmaceutical and healthcare industry.

Competitive intelligence, Saudi Arabian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Saudi Arabian market.

The Saudi Arabia Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to 2011 covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.

Its Saudi Arabia Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Saudi Arabian pharmaceutical and healthcare industry.

Key Benefits of Report
Benchmark Its Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Saudi Arabia to test other views – a key input for successful budgeting and strategic business planning in the Saudi Arabian pharmaceutical and healthcare market.

Target Business Opportunities & Risks in the Saudi Arabian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Saudi Arabia.

Exploit The Latest Competitive Saudi Arabian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Saudi Arabia.

Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect Its forecast analysis, and taken together with Its Economic and Business Environment SWOTS, give a complete overview of market climate.

Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.

Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.

Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.

It 5-Year Industry Forecast
5-Year Forecasts to end-2011 for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp

Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system

OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)

Generics market (US$bn)/ as % of total market

Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population

Forecasts based on bespoke It economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.

It 5-Year Macroeconomic Forecasts
It forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt

Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. It profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.

Executive Summary

The Sector At A Glance

Key Insights On The Pharmaceutical Sector Of Saudi Arabia

The Saudi Arabian pharmaceutical market is the largest in the Arabian Gulf region and was worth an estimated US$1.14bn in 2005. However, It cautions that growth will be sluggish despite favourable economic conditions in the country. This is primarily due to tight price controls. Products can be sold in the country only after the Ministry of Health (MoH) has approved their prices. US drug industry association PhRMA says that these controls act as a considerable barrier to investment. The body also alleges that the MoH discriminates in favour of local drug firms, which have their prices reviewed every five years, compared to four years for foreign companies.

Imports dominate the market, accounting for around 90% of drug consumption, because of the traditional wealth of the country. However, the government is looking to curb health spending – recently introducing mandatory insurance for expatriates – and is encouraging generic substitution. This should provide a boost to domestic manufacturers, with Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO) the most likely beneficiary. SPIMACO is the leading domestic drugmaker and has recently recorded strong results. In Q306, company profits grew 15.1%, on the back of rising sales. Projects include investing in a number of production areas and developing commercial trademarks. This strategy could be aided by plans to establish a regional trademark office for the GCC. Such a development would be a positive step for the trade bloc and represent a milestone for the protection of intellectual property rights in the region. It is hoped that a regional patent office will also soon be established.

Its adjusted Business Environment Rankings for the Middle East and Africa region reveal that Saudi Arabia is in seventh place. This is primarily due to forecasts of average market growth coupled with the country’s intellectual property (IP) regime. Despite new provisions to move the IP regime into line with the World Trade Organisation (WTO)’s Trade-Related Aspects of Intellectual Property Rights (TRIPS) pact, the regime remains below international requirements. However, on a positive note, the size of the market is enticing, and the Saudi government is providing incentives such as interest-free capital and subsidised utility costs to encourage local and foreign players to establish manufacturing facilities

For more information, Please visit :
http://www.bharatbook.com/detail.asp?id=18746

Website: www.bharatbook.com